Efgartigimod in late onset generalized myasthenia gravis with anti-AChr antibodies

Puntos clave

• Improvement in immune response was observed in subjects treated with efgartigimod, indicating its therapeutic benefits.
• The study reports a significant impact on symptoms in patients with anti-AChr antibodies, enhancing their quality of life.
• This observational analysis across multiple cases provides a comprehensive overview of efgartigimod’s efficacy.
• Further studies are needed to validate these findings and assess long-term treatment outcomes.